Actively Recruiting
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Led by Navy General Hospital, Beijing · Updated on 2024-01-30
40
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
CONDITIONS
Official Title
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed Hodgkin Lymphoma according to World Health Organization classification
- Age 18 years or older at the time of signing informed consent
- Ability and willingness to voluntarily sign informed consent before study procedures
- Willingness and ability to follow the study visit schedule and protocol requirements
- Relapsed or refractory angioimmunoblastic T-cell lymphoma after at least one systemic therapy
- Meet lab criteria: Absolute Neutrophil Count ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement), Platelet count ≥ 75 x 10^9/L (≥ 50 x 10^9/L if bone marrow involvement), Hemoglobin ≥ 8 g/dL
- Expected life expectancy of at least 3 months
You will not qualify if you...
- Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment
- Unstable systemic disease including severe cardiac, liver, kidney, or metabolic conditions requiring therapy
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here